Skip to content

Rituximab

    Brands

    DEA Class; Rx

    Common Brand Names; Rituxan, Truxima, rituximab-abbs, Ruxience, rituximab-pvvr, rituximab-arrx, Riabni

    • DMARDs, Other; 
    • Antineoplastics, Anti-CD20 Monoclonal Antibodies

    Anti-CD20 monoclonal antibody
    Used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris
    Boxed warnings for severe infusion-related and mucocutaneous reactions, risk of hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy

    Indicated for treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent

    Indicated in previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab product in combination with chemotherapy, as single-agent maintenance therapy

    Indicated for treatment in patients with nonprogressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy

    Indicated for treatment in patients with previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens

    Indicated for untreated and previously treated CD20-positive CLL; combined therapy with fludarabine and cyclophosphamide (FC)

    Indicated, in combination with methotrexate, for treatment of moderately-to severely-active rheumatoid arthritis (RA) who have had an inadequate response to ≥1 tumor necrosis factor (TNF) antagonist therapies

    Indicated for adults with granulomatosis with polyangiitis (GPA; Wegener granulomatosis) in combination with glucocorticoids

    Indicated for adults with microscopic polyangiitis (MPA) in combination with glucocorticoids

    —

    • Angioedema (11%)
    • Asthenia (26%), chills (33%), dizziness (10%), fever (53%), headache (19%)
    • Pruritus (14%), rash (15%)
    • Abdominal pain (14%), diarrhea (10%), nausea (23%), vomiting (10%)
    • Leukopenia (14%), lymphopenia (48%), neutropenia (14%), thrombocytopenia (12%)
    • Back pain (10%), myalgia (10%)
    • Cough (13%), rhinitis (12%)
    • Infection (31%), night sweats (15%)
    • Nausea (18%)
    • Diarrhea (17%)
    • Headache (17%)
    • Muscle spasms (17%)
    • Anemia (16%)
    • Peripheral edema (16%)
    • Insomnia (14%)
    • Arthralgia (13%)
    • Cough (13%)
    • Fatigue (13%)
    • Increased ALT (13%)
    • Hypertension (12%)
    • Epistaxis (11%)

    —

    Verify pregnancy status in females of reproductive potential prior to initiating therapy

    Data unavailable on drug presence in human milk, effects on breastfed children, or effects on milk production

    Adults

    Chronic lymphocytic leukemia (CLL): 500 mg/m2 IV.Non-Hodgkin lymphoma (NHL), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA): 375 mg/m2 IV.Rheumatoid arthritis (RA) and pemphigus vulgaris (PV): 1,000 mg IV.

    Geriatric

    CLL: 500 mg/m2 IV.NHL, GPA, and MPA: 375 mg/m2 IV.RA and PV: 1,000 mg IV.

    Adolescents

    NHL or mature B-cell acute leukemia (B-AL), GPA, and MPA only: 375 mg/m2 IV.

    Children

    2 to 12 yearsNHL or B-AL, GPA, and MPA: 375 mg/m2 IV.1 yearNHL or B-AL only: 375 mg/m2 IV.

    Infants

    6 months or olderNHL or B-AL only: 375 mg/m2 IV.Less than 6 monthsSafety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Rituximab

    injectable solution (single-dose vials)

    • 10mg/mL (10mL, 50mL vials)

    Biosimilars to Rituxan

    • Riabni (rituximab-arrx)
    • Ruxience (rituximab-rituximab-pvvr)
    • Truxima (rituximab-abbs)